Drug intelligence / Profile preview

lactobacillus rhamnosus grx10

Development stage: Unknown
Lead developer: New Hope Dairy
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus rhamnosus GRX10 is a specific probiotic bacterial strain developed by New Hope Dairy Holding Co., Ltd. in collaboration with academic institutions such as Sichuan University. It is primarily investigated for its metabolic benefits, specifically its potential to improve plasma lipid profiles in individuals with dyslipidemia. As a live biotherapeutic, the strain is thought to exert its effects by modulating the composition of the gut microbiota, enhancing the production of short-chain fatty acids, and potentially interfering with the enterohepatic circulation of bile acids, which collectively contributes to the lowering of serum cholesterol and triglyceride levels.

Other names: L. rhamnosus GRX10

Beyond the preview

Go deeper on lactobacillus rhamnosus grx10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus rhamnosus grx10.

Explore the full profile